Abstract:Clinical trials of the PET amyloid imaging agent (18)F-flutemetamol have used visual assessment to classify PET scans as negative or positive for brain amyloid. However, quantification provides additional information about regional and global tracer uptake and may have utility for image assessment over time and across different centers. Using postmortem brain neuritic plaque density data as a truth standard to derive a standardized uptake value ratio (SUVR) threshold, we assessed a fully automated quantification method comparing visual and quantitative scan categorizations. We also compared the histopathology-derived SUVR threshold with one derived from healthy controls. Methods: Data from 345 consenting subjects enrolled in 8 prior clinical trials of (18)F-flutemetamol injection were used. We grouped subjects into 3 cohorts: an autopsy cohort (n = 68) comprising terminally ill patients with postmortem confirmation of brain amyloid status; a test cohort (n = 172) comprising 33 patients with clinically probable Alzheimer disease, 80 patients with mild cognitive impairment, and 59 healthy volunteers; and a healthy cohort of 105 volunteers, used to define a reference range for SUVR. Visual image categorizations for comparison were from a previous study. A fully automated PET-only quantification method was used to compute regional neocortical SUVRs that were combined into a single composite SUVR. An SUVR threshold for classifying scans as positive or negative was derived by ranking the PET scans from the autopsy cohort based on their composite SUVR and comparing data with the standard of truth based on postmortem brain amyloid status for subjects in the autopsy cohort. The derived threshold was used to categorize the 172 scans in the test cohort as negative or positive, and results were compared with categorization using visual assessment. Different reference and composite region definitions were assessed. Threshold levels were also compared with corresponding thresholds derived from the healthy group. Results: Automated quantification (using pons as the reference region) demonstrated 91% sensitivity and 88% specificity and gave 3 false-positive and 4 false-negative scans. All 3 false-positive cases were either borderline-normal by standard of truth or had moderate to heavy cortical diffuse plaque burden. In the test cohort, the concordance between quantitative and visual read categorization ranged from 97.1% to 99.4% depending on the selection of reference and composite regions. The threshold derived from the healthy group was close to the histopathology-derived threshold. Conclusion: Categorization of (18)F-flutemetamol amyloid imaging data using an automated PET-only quantification method showed good agreement with histopathologic classification of neuritic plaque density and a strong concordance with visual read results.

Image reconstruction parameters and the standardized uptake value ratios in brain amyloid PET

Evaluation of imaging protocol for ECT based on CS image reconstruction algorithm

New quantitative indices of cardiac amyloidosis with 99mTc-pyrophosphate scintigraphy

Impact of quantitative index derived from 123I-FP-CIT-SPECT on reconstruction with correction methods evaluated using a 3D-striatum digital brain phantom

New objective simple evaluation methods of amyloid PET/CT using whole-brain histogram and Top20%-Map

Optimization of penalization function in Bayesian penalized likelihood reconstruction algorithm for [18F]flutemetamol amyloid PET images

Automated PET-only quantification of amyloid deposition with adaptive template and empirically pre-defined ROI

International Nuclear Medicine Consensus on the Clinical Use of Amyloid Positron Emission Tomography in Alzheimer’s Disease

Comparison of two semi‐quantitative amyloid PET analysis methods with and without MRI in Alzheimer’s Disease Spectrum Disorder

Impact of list-mode reconstruction and image-space point spread function correction on PET image contrast and quantitative value using SiPM-based PET/CT system

The Image Quality, Amyloid-Β Detectability, and Acquisition Time of Clinical Florbetapir Positron Emission Tomography in Alzheimer's Disease and Healthy Adults.

Optimization of the reconstruction parameters in [123I]FP-CIT SPECT

Parametric Estimation of Reference Signal Intensity in the Quantification of Amyloid-Beta Deposition: an 18F-AV-45 Study.

Impact of CT and 137 Cs Attenuation Correction on the Quality and Standardized Uptake Value of PET Imaging

The impact of different reconstruction parameters on quantitative 99mTc-DPD SPECT/CT values in the assessment of cardiac transthyretin amyloidosis

Improved Comparability Between Measurements of Mean Cortical Amyloid Plaque Burden Derived from Different PET Tracers Using Multiple Regions‐of‐interest and Machine Learning

Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads

The influence of different signal-to-background ratios on spatial resolution and F18-FDG-PET quantification using point spread function and time-of-flight reconstruction

Kinetic Analysis of Cardiac Dynamic 18F-Florbetapir PET in Healthy Volunteers and Amyloidosis Patients: A Pilot Study

Crossover evaluation of time-of-flight-based attenuation correction in brain 18F-FDG and 18F-flutemetamol PET

IC‐P‐011: Amyloid PET Imaging Using AZD4694 and Unusually Brief Radiotracer Uptake and Scanning Periods